Study to Evaluate the Efficacy and Safety of OxabactTM on Reduction of Urinary Oxalate in Primary Hyperoxaluria Patients

NCT ID: NCT00638703

Last Updated: 2013-05-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 43 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-10-31
• Study Completion Date: 2008-10-31

Brief Summary

The main purpose of this study is to determine if Oxalobacter formigenes is effective at lowering urinary oxalate levels in patients with primary hyperoxaluria.

Conditions

Primary Hyperoxaluria

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

I

Size 2 enteric coated capsule containg lyophilized Oxalobacter formigenes

Group Type: EXPERIMENTAL

Oxalobacter formigenes

Intervention Type: BIOLOGICAL

NLT (not less than) 10\^7 CFU Oxalobacter formigenes twice daily for 24 weeks

II

Size 2 enteric coated capsule containg placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

placebo

Interventions

Oxalobacter formigenes

NLT (not less than) 10\^7 CFU Oxalobacter formigenes twice daily for 24 weeks

Intervention Type: BIOLOGICAL

Placebo

placebo

Intervention Type: DRUG

Other Intervention Names

- Oxabact(tm); - OC3

Eligibility Criteria

Inclusion Criteria

1. The subject (or legally acceptable representative) must give written informed consent (and assent for subjects ≥ 12 years or country specific age as appropriate). For subjects less than 18 years of age, parent or guardian will provide informed consent and the subject will provide witnessed verbal assent

2. Male or female subjects ≥ 5 years of age

3. Urinary oxalate excretion of > 1.0 mmol/1.73m2/day at Baseline

4. Documentation of diagnosis of PH I or PH II by any one of the following:

1. Liver biopsy confirmation of deficient liver specific peroxisomal alanine-glyoxylate aminotransferase, (AGT) or mislocalization of AGT from peroxisomes to mitochondria (PH I) or deficient glyoxylate reductase/hydroxypyruvate reductase (GR/HPR) activity (PH II)

2. Homozygosity or compound heterozygosity for a known mutation in the causative genes for PH I and PH II

3. Increased glycolate excretion for PH I or increased L-glycerate excretion for PH II

5. Subjects receiving pyridoxine must be receiving a stable dose for at least 3 months prior to entry in to the study and must remain on the stable dose during the study. Other (non-pyridoxine naïve) subjects (e.g. Pyridoxine non-responder: <30% reduction of the urine oxalate levels) not receiving pyridoxine at study entry must be willing to refrain from initiating pyridoxine during study participation. Note: There will be no pyridoxine-naïve subjects enrolled in the study.

6. Renal function defined as an estimated GFR ≥ 50 ml/min normalized to 1.73m2 body surface area

Exclusion Criteria

1. Pregnant, lactating, or actively menstruating women and women of child-bearing potential who are not using adequate contraceptive precautions. Sexually active females, unless surgically sterile or at least 2 years post-menopausal, must be using a highly effective contraception (including oral, transdermal, injectable, or implanted contraceptives, IUD, abstinence, use of a condom by the sexual partner, or sterile sexual partner) for 30 days prior to the first dose of OxabactTM and must agree to continue using such precautions during the clinical study.

Note: A highly effective method of birth control is defined as one that results in a low failure rate (i.e. less than 1% per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, some intrauterine contraceptive devices (IUDs), sexual abstinence, or a vasectomised partner.

2. Positive serum pregnancy test.

3. Participation in any study of an investigational product, biologic, device, or other agent within 30 days prior to randomization or not willing to forego other forms of investigational treatment during this study.

4. Subjects on hemodialysis or peritoneal dialysis.

5. Subjects who have undergone transplantation (solid organ or bone marrow).

7. Current systemic (oral, IM, IV) antibiotic use or received systemic antibiotics within 14 days of study enrolment.

8. History of chronic, recurrent infections requiring >2 courses of antibiotics in the past 6 months.

9. History of malignancy except for basal or squamous cell skin cancer that has been excised.

10. Unable to collect 24-hour urine samples or follow other study procedures.

11. Subjects who cannot swallow a size 2 capsule.

12. Presence of a medical condition that the Principal Investigator considers likely to make the subject susceptible to adverse effect of study treatment or unable to follow study procedures.

13. Subjects who require immune suppressive therapy (including prednisone of > 10mg daily for more than 2 weeks).

14. Subjects from correctional facilities or asylums.

15. Subjects who are mentally handicapped.

• Minimum Eligible Age: 5 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

OxThera

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Dawn Milliner, M.D

Role: PRINCIPAL_INVESTIGATOR

Mayo Clinic

Locations

Mayo Clinic (Department of Pediatric Nephrology)

Rochester, Minnesota, United States

Countries

United States

Other Identifiers

DB-01

Identifier Type: -

Identifier Source: secondary_id

OC3-DB-01

Identifier Type: -

Identifier Source: org_study_id